📢 𝗝𝗨𝗦𝗧 𝗜𝗡: $Eli Lilly(LLY.US) Eli Lilly's O

📢 𝗝𝗨𝗦𝗧 𝗜𝗡: $Eli Lilly(LLY.US) Eli Lilly's Olomorasib Receives FDA Breakthrough Therapy Designation for Pancreatic Cancer

👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:

➤ 𝗘𝗹𝗶 𝗟𝗶𝗹𝗹𝘆's 𝗼𝗹𝗼𝗺𝗼𝗿𝗮𝘀𝗶𝗯 receives 𝗙𝗗𝗔 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 designation.

➤ Designation covers previously treated 𝗞𝗥𝗔𝗦 𝗚𝟭𝟮𝗖-mutant advanced pancreatic cancer.

➤ Olomorasib is a next-generation 𝗞𝗥𝗔𝗦 𝗚𝟭𝟮𝗖 inhibitor under investigation.

➤ FDA designation is intended to accelerate drug development and review.

➤ No approved targeted therapies currently exist for 𝗞𝗥𝗔𝗦 𝗚𝟭𝟮𝗖-mutant pancreatic cancer.

➤ Decision is based on preliminary 𝗣𝗵𝗮𝘀𝗲 𝟭/𝟮 𝗟𝗢𝗫𝗢-𝗥𝗔𝗦-𝟮𝟬𝟬𝟬𝟭 trial results.

➤ Olomorasib previously received Breakthrough Therapy designation in 𝗞𝗥𝗔𝗦 𝗚𝟭𝟮𝗖-mutant NSCLC.

➤ Lilly continues evaluating olomorasib across multiple 𝗞𝗥𝗔𝗦 𝗚𝟭𝟮𝗖-driven cancers.

👉 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀:

➤ FDA designation may accelerate regulatory review and clinical development.

➤ Addresses a major unmet need in a cancer with limited treatment options.

➤ Expands Lilly's oncology pipeline in precision cancer therapies.

➤ Reinforces momentum for 𝗞𝗥𝗔𝗦-targeted cancer drug development.

👉 𝗘𝘅𝗽𝗲𝗿𝘁 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁:

𝗝𝗮𝗰𝗼𝗯 𝗩𝗮𝗻 𝗡𝗮𝗮𝗿𝗱𝗲𝗻, Executive Vice President and President of Lilly Oncology:

"Pancreatic cancer has historically been one of the most difficult-to-treat cancers and people whose tumors harbor a KRAS G12C mutation face limited options once their disease progresses. This Breakthrough Therapy designation reflects the early potential we're seeing with olomorasib in this setting and the critical need for new treatment options. With now two Breakthrough Therapy designations across pancreatic and lung cancers, olomorasib continues to demonstrate broad potential clinical evidence across KRAS G12C-driven tumors and reflects our commitment to bringing meaningful new treatment options to patients living with these cancers."